These findings indicated that the NSCLC metastasis mechanism could be regulated by EGFR-PI3K/AKT-FOXA1-PLOD2 pathway and PLOD2 can be a therapeutic target for NSCLC treatment (161). This evidence concerns the gene PLOD2 and non-small cell lung carcinoma.